These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28917334)

  • 21. Calling time on the immunotherapy gold rush.
    The Lancet Oncology
    Lancet Oncol; 2017 Aug; 18(8):981. PubMed ID: 28759366
    [No Abstract]   [Full Text] [Related]  

  • 22. [Not Available].
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(4):263a. PubMed ID: 29176294
    [No Abstract]   [Full Text] [Related]  

  • 23. Is gut microbiome a predictive marker to response to immune checkpoint inhibitors?
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2017 Sep; 9(11):865-866. PubMed ID: 29251088
    [No Abstract]   [Full Text] [Related]  

  • 24. Sarcoidosis, malignancy and immune checkpoint blockade.
    Gaughan EM
    Immunotherapy; 2017 Oct; 9(13):1051-1053. PubMed ID: 29032735
    [No Abstract]   [Full Text] [Related]  

  • 25. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.
    Yshii LM; Hohlfeld R; Liblau RS
    Nat Rev Neurol; 2017 Dec; 13(12):755-763. PubMed ID: 29104289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the imaging manifestations of immune check point inhibitor toxicities.
    Thomas R; Sebastian B; George T; Majeed NF; Akinola T; Laferriere SL; Braschi-Amirfarzan M
    Clin Imaging; 2020 Aug; 64():70-79. PubMed ID: 32334270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors and elderly people: A review.
    Daste A; Domblides C; Gross-Goupil M; Chakiba C; Quivy A; Cochin V; de Mones E; Larmonier N; Soubeyran P; Ravaud A
    Eur J Cancer; 2017 Sep; 82():155-166. PubMed ID: 28689093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
    Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
    Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
    Arangalage D; Delyon J; Lermuzeaux M; Ekpe K; Ederhy S; Pages C; Lebbé C
    Ann Intern Med; 2017 Nov; 167(9):683-684. PubMed ID: 28869988
    [No Abstract]   [Full Text] [Related]  

  • 30. [Neurological side effects of checkpoint inhibitors].
    Knauss S; Ginesta Roque L; Hühnchen P; Heinzerling L; Böhmerle W; Endres M
    Nervenarzt; 2019 Feb; 90(2):138-147. PubMed ID: 30073487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy.
    Wang PF; Song HF; Zhang Q; Yan CX
    Eur J Cancer; 2020 Feb; 126():136-138. PubMed ID: 31927214
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection.
    Ros J; Matos I; Martin-Liberal J
    Ann Oncol; 2019 Jul; 30(7):1173-1177. PubMed ID: 30977776
    [No Abstract]   [Full Text] [Related]  

  • 33. A reality check of the accelerated approval of immune-checkpoint inhibitors.
    Gill J; Prasad V
    Nat Rev Clin Oncol; 2019 Nov; 16(11):656-658. PubMed ID: 31383994
    [No Abstract]   [Full Text] [Related]  

  • 34. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.
    Thompson JA
    J Natl Compr Canc Netw; 2018 May; 16(5S):594-596. PubMed ID: 29784734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurologic complications of immune checkpoint inhibitors.
    Fellner A; Makranz C; Lotem M; Bokstein F; Taliansky A; Rosenberg S; Blumenthal DT; Mandel J; Fichman S; Kogan E; Steiner I; Siegal T; Lossos A; Yust-Katz S
    J Neurooncol; 2018 May; 137(3):601-609. PubMed ID: 29332184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue.
    Roviello G; Generali D; Ianza A
    Immunotherapy; 2019 Apr; 11(5):365-368. PubMed ID: 30786842
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiothoracic Complications of Immune Checkpoint Inhibitor Therapy: An Imaging Review.
    Agarwal S; Healey TT
    J Comput Assist Tomogr; 2020; 44(5):652-655. PubMed ID: 32842069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD1 inhibitors and hair repigmentation: A desirable new side effect.
    Correa-Selm LM; Grichnik JM
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29034554
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune checkpoint inhibitors and the union of bugs against cancer.
    Silverman GJ; Azzouz DF; Mor A
    Kidney Int; 2018 May; 93(5):1030-1032. PubMed ID: 29680016
    [No Abstract]   [Full Text] [Related]  

  • 40. Optimal design and endpoint of clinical trials using immune checkpoint blocking agents.
    Keam B; Jung H; Nam BH
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1217-1218. PubMed ID: 27740862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.